Press Release
<p>FERRING PHARMACEUTICALS ANNOUNCES TRADE NAME FIRMAGON<sup><sup>®</sup></sup> (degarelix for injection) FOR ADVANCED PROSTATE CANCER TREATMENT</p>
<p><b>PARSIPPANY, NJ – August 4, 2009 –</b> Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON<sup>®</sup> (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix, FIRMAGON has been used by more than 3,000 patients to fight their prostate cancer.</p>
<p>“This treatment was in development by Ferring Pharmaceuticals in the U.S. and Europe for more than a decade,” said Wayne Anderson, President and CEO of Ferring Pharmaceuticals Inc., USA. “We launched degarelix prior to receiving approval for its brand name in order to bring the medical community an effective alternative in the treatment of advanced prostate cancer without delay. We plan to continue our research in the area of urology and we expect to introduce additional treatment advances in the future.”</p>
<p>FIRMAGON provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth.<sup>1-3</sup> Phase III pivotal studies showed that FIRMAGON is as effective as leuprolide (Lupron Depot<sup>®</sup>)* in reducing and sustaining castrate levels of testosterone.<sup>1,2</sup> Suppression of testosterone to castrate levels occurred significantly faster in patients receiving FIRMAGON than in those receiving leuprolide.<sup>1,2</sup> At Day 3 of treatment, the FIRMAGON group achieved a 90 percent decrease in median testosterone levels compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels, a statistically significant result. FIRMAGON was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the FIRMAGON patients maintaining medical castrate levels compared with 96.4 percent for leuprolide.</p>
<p>In addition, prostate-specific antigen (PSA) levels were lowered by 64 percent two weeks after administration of FIRMAGON, 85 percent after one month, 95 percent after three months, and remained suppressed throughout the one year of treatment.<sup>1,2</sup> These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit. FIRMAGON is the exact same product as degarelix and carries the same National Drug Code (NDC). FIRMAGON is being reimbursed by all Medicare Administrative Carriers and virtually all commercial insurers. A free reimbursement assistance hotline for FIRMAGON is available at 1-877-971-3778 and has already assisted hundreds of patients and physician offices. Centers for Medicare & Medicaid Services (CMS) reimbursement rates are on their Web site and can be accessed at <a href="http://tinyurl.com/kl79hr">http://tinyurl.com/kl79hr</a>. For complete prescribing information, visit <a href="http://www.firmagon.com/">www.FIRMAGON.com</a>.</p>
<p><b>About FIRMAGON</b></p>
<p>FIRMAGON is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. As a receptor antagonist, FIRMAGON reversibly binds to the GnRH receptors in the pituitary gland, immediately suppressing the secretion of the luteinizing hormone (LH), follicle-stimulating hormone (FSH), and subsequently, testosterone levels.<sup>4</sup> FIRMAGON also reduces levels of prostate-specific antigen (PSA). Unlike luteinizing hormonereleasing hormone (LHRH) agonists, such as leuprolide, an established treatment for prostate cancer, FIRMAGON does not induce an initial testosterone surge. FIRMAGON is administered monthly by subcutaneous injection. The starting dose is 240 mg, followed by monthly maintenance doses of 80 mg. FIRMAGON is available for order through traditional and specialty pharmacy distributors. The average monthly cost of one year of FIRMAGON treatment is comparable to other hormone treatments for prostate cancer.</p>
<p>The most commonly observed adverse reactions during FIRMAGON therapy included injection site reactions (e.g. pain, erythema, swelling or induration), hot flashes, increased weight, fatigue, and increases in serum levels of transaminases and gammaglutamyltransferase (GGT). Ninety-nine percent of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of patients receiving FIRMAGON.</p>
<p>FIRMAGON is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. FIRMAGON is not indicated in women or pediatric patients. Long-term androgen deprivation therapy prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients
with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.</p>
<p><b>About Ferring Pharmaceuticals Inc.</b></p>
<p>Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE<sup>®</sup> (urofollitropin for injection, purified), MENOPUR<sup>®</sup> and REPRONEX<sup>®</sup> (menotropins for injection, USP), NOVAREL<sup>®</sup> (chorionic gonadotropin for injection, USP), ENDOMETRIN<sup>®</sup> (progesterone) Vaginal Insert, 100 mg, FIRMAGON<sup>®</sup> (degarelix for injection), PROSED<sup>®</sup> DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA<sup>®</sup> (1% sodium hyaluronate).</p>
<p>Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit <a href="http://www.ferringusa.com/">www.FerringUSA.com</a>.</p>
<p>*Lupron Depot<sup>®</sup> (leuprolide acetate for depot suspension) is a registered trademark of TAP
Pharmaceuticals Inc.</p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
Find an OA
knee pain doctor
near you
knee pain doctor
near you
See How
Euflexxa
Has Helped
Others
Euflexxa
Has Helped
Others
Take the
Self-Assessment
Quiz
Self-Assessment
Quiz
Download Our
Patient Education
Brochure
Patient Education
Brochure
 |
SIGN UP FOR NEWS ABOUT OA OF THE KNEE |
